Checkpoint inhibitors (ICI) such as anti-CTLA4 (ipilimumab), anti-PD1 (pembrolizumab, nivolumab, cemiplimab, dostarlimab, retifanilab), anti-PD-L1 (atezolizumab, avelumab, durvalumab), anti-LAG-3 (relatlimab) and anti-TIGIT (tiragolumab) antibodies have been effective in treating multiple tumour types [1]. The gene discussed is CTLA4; the disease is neoplasm.